Platelet-Derived Growth Factor Is Associated with Progression of Symptomatic Intracranial Atherosclerotic Stenosis.
intracranial stenosis
ischemic stroke
magnetic resonance angiography
platelet-derived growth factor
Journal
Journal of clinical neurology (Seoul, Korea)
ISSN: 1738-6586
Titre abrégé: J Clin Neurol
Pays: Korea (South)
ID NLM: 101252374
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
17
07
2020
revised:
21
09
2020
accepted:
21
09
2020
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
ppublish
Résumé
We aimed to determine the relationships of 33 biomarkers of inflammation, oxidation, and adipokines with the risk of progression of symptomatic intracranial atherosclerotic stenosis (ICAS). Fifty-two of 409 patients who participated in the TOSS-2 (Trial of Cilostazol in Symptomatic Intracranial Stenosis-2) showed progression of symptomatic ICAS in magnetic resonance angiography at 7 months after an index stroke. We randomly selected 20 patients with progression as well as 40 age- and sex-matched control patients. We serially collected blood samples at baseline, 1 month, and 7 months after an index stroke. Multiplex analysis of biomarkers was then performed. Demographic features and risk factors such as hypertension, diabetes, and smoking history were comparable between the two groups. Univariate analyses revealed that the levels of platelet-derived growth factor (PDGF)-AA [median (interquartile range)=1.64 (0.76-4.57) vs. 0.77 (0.51-1.71) ng/mL], PDGF-AB/BB [10.31 (2.60-25.90) vs. 2.35 (0.74-6.70) ng/mL], and myeloperoxidase [10.5 (7.5-22.3) vs. 7.8 (5.5-12.2) ng/mL] at 7 months were higher in the progression group. In the multivariate analysis using logistic regression, the PDGF AB/BB level at 7 months was independently associated with the progression of ICAS ( The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
We aimed to determine the relationships of 33 biomarkers of inflammation, oxidation, and adipokines with the risk of progression of symptomatic intracranial atherosclerotic stenosis (ICAS).
METHODS
METHODS
Fifty-two of 409 patients who participated in the TOSS-2 (Trial of Cilostazol in Symptomatic Intracranial Stenosis-2) showed progression of symptomatic ICAS in magnetic resonance angiography at 7 months after an index stroke. We randomly selected 20 patients with progression as well as 40 age- and sex-matched control patients. We serially collected blood samples at baseline, 1 month, and 7 months after an index stroke. Multiplex analysis of biomarkers was then performed.
RESULTS
RESULTS
Demographic features and risk factors such as hypertension, diabetes, and smoking history were comparable between the two groups. Univariate analyses revealed that the levels of platelet-derived growth factor (PDGF)-AA [median (interquartile range)=1.64 (0.76-4.57) vs. 0.77 (0.51-1.71) ng/mL], PDGF-AB/BB [10.31 (2.60-25.90) vs. 2.35 (0.74-6.70) ng/mL], and myeloperoxidase [10.5 (7.5-22.3) vs. 7.8 (5.5-12.2) ng/mL] at 7 months were higher in the progression group. In the multivariate analysis using logistic regression, the PDGF AB/BB level at 7 months was independently associated with the progression of ICAS (
CONCLUSIONS
CONCLUSIONS
The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS.
Identifiants
pubmed: 33480201
pii: 17.70
doi: 10.3988/jcn.2021.17.1.70
pmc: PMC7840326
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70-76Subventions
Organisme : Korea Otsuka International Asia, and Arab Co, Ltd
Pays : Korea
Organisme : Dongguk University
Pays : Korea
Informations de copyright
Copyright © 2021 Korean Neurological Association.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
Atherosclerosis. 2011 Jan;214(1):185-90
pubmed: 21067752
J Leukoc Biol. 2010 May;87(5):779-89
pubmed: 20130219
J Stroke Cerebrovasc Dis. 2013 Apr;22(3):211-7
pubmed: 22000523
Stroke. 2005 Apr;36(4):782-6
pubmed: 15746463
Science. 1988 Jun 10;240(4858):1529-31
pubmed: 2836952
Trends Genet. 1989 Apr;5(4):108-11
pubmed: 2543106
Circulation. 2005 Nov 22;112(21):3215-7
pubmed: 16301352
Cytokine Growth Factor Rev. 2004 Aug;15(4):237-54
pubmed: 15207815
Stroke. 2008 May;39(5):1456-63
pubmed: 18323504
Atherosclerosis. 2009 Jul;205(1):74-9
pubmed: 19110249
Res Publ Assoc Res Nerv Ment Dis. 1966;41:1-22
pubmed: 5334399
Biochim Biophys Acta. 1989 Jul 28;989(1):1-10
pubmed: 2546599
Circulation. 2001 Jun 19;103(24):2955-60
pubmed: 11413086
Biochim Biophys Acta. 1998 Aug 19;1378(1):F79-113
pubmed: 9739761
Stroke. 2002 Feb;33(2):532-6
pubmed: 11823665
Circ Cardiovasc Imaging. 2014 Jul;7(4):619-28
pubmed: 24782115
Circulation. 2005 Nov 22;112(21):3272-9
pubmed: 16286589
Arterioscler Thromb Vasc Biol. 2004 May;24(5):935-42
pubmed: 14988091
Stroke. 2008 Aug;39(8):2396-9
pubmed: 18535283
N Engl J Med. 2005 Mar 31;352(13):1305-16
pubmed: 15800226
J Korean Med Sci. 2001 Apr;16(2):198-203
pubmed: 11306747
Stroke. 2011 Oct;42(10):2883-90
pubmed: 21799173
Ann Vasc Surg. 2009 Sep-Oct;23(5):652-62
pubmed: 19467827
Proc Natl Acad Sci U S A. 1979 Aug;76(8):3722-6
pubmed: 291037
Cytokine. 2012 Oct;60(1):302-8
pubmed: 22704695
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2657-62
pubmed: 11116068
Int J Cardiol. 2011 Feb 17;147(1):4-12
pubmed: 20692712
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
Stroke. 2001 Dec 1;32(12):2898-904
pubmed: 11739993